News & Events
Monoceros Biosystems, a leading bioinformatics/computational biology provider, is pleased to announce the appointment of Jonathan Spier to its Board of Directors
We are delighted to announce the appointment of Jonathan Spier, MBA, to our Board. With over 20 years of experience building category-leading companies, Jonathan is a seasoned leader whose expertise spans marketing, business operations, and strategic growth. Currently, Jonathan serves as CEO of GetRev and Rev Intelligence, innovative companies at the forefront of AI, empowering B2B sales and marketing teams to drive more effective and efficient go-to-market strategies. Previously, [...]
Monoceros Biosystems, a leading bioinformatics/computational biology provider, is pleased to announce the appointment of Regan Lohman to its Board of Directors
We are thrilled to announce the appointment of Regan Lohman to our Board. Regan is the founder & CEO of Lohman & Associates, Inc., a leading life science focused, outsourced finance and accounting firm. With 16 years of extensive experience in accounting, finance, and auditing, Regan brings a wealth of expertise to our board. Regan's collaborative approach has seen her partner with companies across various stages of growth, providing invaluable [...]
Monoceros Biosystems and SeekIn Join Forces to Pave the Way for Cutting-Edge AI-Powered Cancer Diagnostics
San Diego, September 21, 2023 – Monoceros Biosystems, a prominent bioinformatics service provider in the United States, is thrilled to announce a strategic partnership with SeekIn, a leading blood testing provider in China, to embark on a groundbreaking collaboration aimed at revolutionizing the field of blood cancer testing. The partnership represents a significant milestone in the quest to advance early cancer detection and disease monitoring through state-of-the-art genomics and bioinformatics [...]
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Mirati Therapeutics, in collaboration with Monoceros Biosystems and leading academic instituations, published a novel Cancer Discovery article entitled “MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer“ Read Article
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Mirati Therapeutics, in collaboration with Array BioPharma (Pfizer) and Monoceros Biosystems, published a novel Nature Medicine article entitled "Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor" Read Article